@article{3184270,
    title = "International myeloma working group consensus recommendations on imaging
in monoclonal plasma cell disorders",
    author = "Hillengass, Jens and Usmani, Saad and Rajkumar, S. Vincent and Durie, and Brian G. M. and Mateos, Maria-Victoria and Lonial, Sagar and Joao, and Cristina and Anderson, Kenneth C. and Garcia-Sanz, Ramon and Riva Serra, and Eloisa and Du, Juan and van de Donk, Niels and Berdeja, Jesus G. and and Terpos, Evangelos and Zamagni, Elena and Kyle, Robert A. and San Miguel, and Jesus and Goldschmidt, Hartmut and Giralt, Sergio and Kumar, Shaji and and Raje, Noopur and Ludwig, Heinz and Ocio, Enrique and Schots, Rik and and Einsele, Hermann and Schjesvold, Fredrik and Chen, Wen-Ming and and Abildgaard, Niels and Lipe, Brea C. and Dytfeld, Dominik and Wirk, and Baldeep Mona and Drake, Matthew and Cavo, Michele and Jose Lahuerta, and Juan and Lentzsch, Suzanne",
    journal = "The lancet oncology",
    year = "2019",
    volume = "20",
    number = "6",
    pages = "E302-E312",
    publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",
    doi = "10.1016/S1470-2045(19)30309-2",
    abstract = "Recent advances in the treatment of multiple myeloma have increased the
need for accurate diagnosis of the disease. The detection of bone and
bone marrow lesions is crucial in the investigation of multiple myeloma
and often dictates the decision to start treatment. Furthermore,
detection of minimal residual disease is important for prognosis
determination and treatment planning, and it has underscored an unmet
need for sensitive imaging methods that accurately assess patient
response to multiple myeloma treatment. Low-dose whole-body CT has
increased sensitivity compared with conventional skeletal survey in the
detection of bone disease, which can reveal information leading to
changes in therapy and disease management that could prevent or delay
the onset of clinically significant morbidity and mortality as a result
of skeletal-related events. Given the multiple options available for the
detection of bone and bone marrow lesions, ranging from conventional
skeletal survey to whole-body CT, PET/CT, and MRI, the International
Myeloma Working Group decided to establish guidelines on optimal use of
imaging methods at different disease stages. These recommendations on
imaging within and outside of clinical trials will help standardise
imaging for monoclonal plasma cell disorders worldwide to allow the
comparison of results and the unification of treatment approaches for
multiple myeloma."
}